Mirum Submits New Drug Application To FDA For Chenodiol For Treatment Of CTX
Mirum Pharmaceuticals +1.67% Pre
Mirum Pharmaceuticals MIRM | 39.54 38.60 | +1.67% -2.38% Pre |
- Submission based on the positive Phase 3 RESTORE study
- Mirum holds orphan designation for chenodiol in CTX
- Potential to have first and only therapy indicated for CTX in the US